{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T09:10:15Z","timestamp":1734253815754,"version":"3.30.2"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,15]]},"DOI":"10.7759\/cureus.75722","type":"journal-article","created":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T08:02:41Z","timestamp":1734249761000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Sequential Treatment From Remdesivir to Molnupiravir for Prolonged COVID-19 in a Patient With Follicular Lymphoma and Renal Pelvic Carcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Tomoki","family":"Satoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Akata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimasa","family":"Tsuruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yatera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1087800","article-title":"Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2","volume":"10","author":"Zhong W","year":"2022","unstructured":"Zhong W, Yang X, Jiang X, et al.. Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2. Front Public Health. 2022, 10:1087800. 10.3389\/fpubh.2022.1087800","journal-title":"Front Public Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2022.12.003","article-title":"Comorbidities prolonged viral shedding of patients infected with SARS-CoV-2 omicron variant in Shanghai: a multi-center, retrospective, observational study","volume":"16","author":"Pei L","year":"2023","unstructured":"Pei L, Chen Y, Zheng X, et al.. Comorbidities prolonged viral shedding of patients infected with SARS-CoV-2 omicron variant in Shanghai: a multi-center, retrospective, observational study. J Infect Public Health. 2023, 16:182-9. 10.1016\/j.jiph.2022.12.003","journal-title":"J Infect Public Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.09.023","article-title":"Clinical factors associated with viral shedding time of SARS-CoV-2 Omicron variant in Japan","volume":"30","author":"Akata K","year":"2024","unstructured":"Akata K, Yamasaki K, Kohrogi R, et al.. Clinical factors associated with viral shedding time of SARS-CoV-2 Omicron variant in Japan. J Infect Chemother. 2024, 30:172-5. 10.1016\/j.jiac.2023.09.023","journal-title":"J Infect Chemother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16935","article-title":"Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience","volume":"190","author":"Shah V","year":"2020","unstructured":"Shah V, Ko Ko T, Zuckerman M, et al.. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020, 190:e279-82. 10.1111\/bjh.16935","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1033","article-title":"Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies","volume":"12","author":"Lee CY","year":"2022","unstructured":"Lee CY, Shah MK, Hoyos D, et al.. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discov. 2022, 12:62-73. 10.1158\/2159-8290.CD-21-1033","journal-title":"Cancer Discov"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb2104756","article-title":"SARS-CoV-2 variants in patients with immunosuppression","volume":"385","author":"Corey L","year":"2021","unstructured":"Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med. 2021, 385:562-6. 10.1056\/NEJMsb2104756","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi B","year":"2020","unstructured":"Choi B, Choudhary MC, Regan J, et al.. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020, 383:2291-3. 10.1056\/NEJMc2031364","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa446","article-title":"Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy","volume":"222","author":"Helleberg M","year":"2020","unstructured":"Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech AM, Lane C, Lundgren J. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020, 222:1103-7. 10.1093\/infdis\/jiaa446","journal-title":"J Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000841","article-title":"Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside","volume":"35","author":"Laracy JC","year":"2022","unstructured":"Laracy JC, Kamboj M, Vardhana SA. Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside. Curr Opin Infect Dis. 2022, 35:271-9. 10.1097\/QCO.0000000000000841","journal-title":"Curr Opin Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad189","article-title":"Successful treatment of prolonged severe acute respiratory syndrome coronavirus 2 infection in patients with immunodeficiency with extended nirmatrelvir\/ritonavir: case series","volume":"10","author":"Breeden M","year":"2023","unstructured":"Breeden M, Aitken SL, Baang JH, et al.. Successful treatment of prolonged severe acute respiratory syndrome coronavirus 2 infection in patients with immunodeficiency with extended nirmatrelvir\/ritonavir: case series. Open Forum Infect Dis. 2023, 10:ofad189. 10.1093\/ofid\/ofad189","journal-title":"Open Forum Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad306","article-title":"Successful treatment of persistent symptomatic coronavirus disease 19 infection with extended-duration nirmatrelvir-ritonavir among outpatients with hematologic cancer","volume":"10","author":"Liu C","year":"2023","unstructured":"Liu C, Yoke LH, Bhattacharyya P, et al.. Successful treatment of persistent symptomatic coronavirus disease 19 infection with extended-duration nirmatrelvir-ritonavir among outpatients with hematologic cancer. Open Forum Infect Dis. 2023, 10:ofad306. 10.1093\/ofid\/ofad306","journal-title":"Open Forum Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac847","article-title":"Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised host","volume":"76","author":"Trottier CA","year":"2023","unstructured":"Trottier CA, Wong B, Kohli R, et al.. Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised host. Clin Infect Dis. 2023, 76:923-5. 10.1093\/cid\/ciac847","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac868","article-title":"Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a b cell acute lymphoblastic leukemia patient with an extended course of remdesivir and nirmatrelvir\/ritonavir","volume":"76","author":"Ford ES","year":"2023","unstructured":"Ford ES, Simmons W, Karmarkar EN, et al.. Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a b cell acute lymphoblastic leukemia patient with an extended course of remdesivir and nirmatrelvir\/ritonavir. Clin Infect Dis. 2023, 76:926-9. 10.1093\/cid\/ciac868","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.04.412","article-title":"Combination regimen of nirmatrelvir\/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: a case report and a scoping review of the literature","volume":"133","author":"Marangoni D","year":"2023","unstructured":"Marangoni D, Antonello RM, Coppi M, et al.. Combination regimen of nirmatrelvir\/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: a case report and a scoping review of the literature. Int J Infect Dis. 2023, 133:53-6. 10.1016\/j.ijid.2023.04.412","journal-title":"Int J Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2023.e01890","article-title":"Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma","volume":"34","author":"Jung S","year":"2023","unstructured":"Jung S, Yagi Y, Fukushima K, et al.. Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma. IDCases. 2023, 34:e01890. 10.1016\/j.idcr.2023.e01890","journal-title":"IDCases"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2603","article-title":"Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir","volume":"112","author":"Singh RS","year":"2022","unstructured":"Singh RS, Toussi SS, Hackman F, et al.. Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir. Clin Pharmacol Ther. 2022, 112:101-11. 10.1002\/cpt.2603","journal-title":"Clin Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe covid-19","volume":"383","author":"Goldman JD","year":"2020","unstructured":"Goldman JD, Lye DC, Hui DS, et al.. Remdesivir for 5 or 10 days in patients with severe covid-19. N Engl J Med. 2020, 383:1827-37. 10.1056\/NEJMoa2015301","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/284101-successful-sequential-treatment-from-remdesivir-to-molnupiravir-for-prolonged-covid-19-in-a-patient-with-follicular-lymphoma-and-renal-pelvic-carcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T08:02:42Z","timestamp":1734249762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/284101-successful-sequential-treatment-from-remdesivir-to-molnupiravir-for-prolonged-covid-19-in-a-patient-with-follicular-lymphoma-and-renal-pelvic-carcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,15]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.75722","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,15]]}}}